相似文献
1
Discovery of Pyrazolocarboxamides as Potent and Selective Receptor Interacting Protein 2 (RIP2) Kinase Inhibitors.
ACS Med Chem Lett. 2019 Oct 11;10(11):1518-1523. doi: 10.1021/acsmedchemlett.9b00141. eCollection 2019 Nov 14.
2
Crystal structures of human RIP2 kinase catalytic domain complexed with ATP-competitive inhibitors: Foundations for understanding inhibitor selectivity.
Bioorg Med Chem. 2015 Nov 1;23(21):7000-6. doi: 10.1016/j.bmc.2015.09.038. Epub 2015 Sep 25.
3
Disruption of XIAP-RIP2 Association Blocks NOD2-Mediated Inflammatory Signaling.
Mol Cell. 2018 Feb 15;69(4):551-565.e7. doi: 10.1016/j.molcel.2018.01.016.
4
Renoprotective Effects of a Novel Receptor-Interacting Protein Kinase 2 Inhibitor, AS3334034, in Uninephrectomized Adriamycin-Induced Chronic Kidney Disease Rats.
J Pharmacol Exp Ther. 2020 Sep;374(3):428-437. doi: 10.1124/jpet.120.265678. Epub 2020 Jun 19.
5
Structures of the inactive and active states of RIP2 kinase inform on the mechanism of activation.
PLoS One. 2017 May 18;12(5):e0177161. doi: 10.1371/journal.pone.0177161. eCollection 2017.
6
Discovery of a First-in-Class Receptor Interacting Protein 2 (RIP2) Kinase Specific Clinical Candidate, 2-((4-(Benzo[]thiazol-5-ylamino)-6-(-butylsulfonyl)quinazolin-7-yl)oxy)ethyl Dihydrogen Phosphate, for the Treatment of Inflammatory Diseases.
J Med Chem. 2019 Jul 25;62(14):6482-6494. doi: 10.1021/acs.jmedchem.9b00575. Epub 2019 Jul 2.
7
Inhibition of RIP2/RIck/CARDIAK activity by pyridinyl imidazole inhibitors of p38 MAPK.
Mol Cell Biochem. 2005 Jan;268(1-2):129-40. doi: 10.1007/s11010-005-3701-0.
8
Discovery of Potent, Selective Triazolothiadiazole-Containing c-Met Inhibitors.
ACS Med Chem Lett. 2021 May 24;12(6):955-960. doi: 10.1021/acsmedchemlett.1c00094. eCollection 2021 Jun 10.
9
RIP2-beta: a novel alternative mRNA splice variant of the receptor interacting protein kinase RIP2.
Mol Immunol. 2009 Mar;46(6):1163-70. doi: 10.1016/j.molimm.2008.11.002. Epub 2009 Jan 3.
10
Identification of Quinoline-Based RIP2 Kinase Inhibitors with an Improved Therapeutic Index to the hERG Ion Channel.
ACS Med Chem Lett. 2018 Sep 26;9(10):1039-1044. doi: 10.1021/acsmedchemlett.8b00344. eCollection 2018 Oct 11.
引用本文的文献
1
CMD-OPT model enables the discovery of a potent and selective RIPK2 inhibitor as preclinical candidate for the treatment of acute liver injury.
Acta Pharm Sin B. 2025 Jul;15(7):3708-3724. doi: 10.1016/j.apsb.2025.05.003. Epub 2025 May 13.
2
AlphaFold-SFA: Accelerated sampling of cryptic pocket opening, protein-ligand binding and allostery by AlphaFold, slow feature analysis and metadynamics.
PLoS One. 2024 Aug 27;19(8):e0307226. doi: 10.1371/journal.pone.0307226. eCollection 2024.
3
RIPK2: a promising target for cancer treatment.
Front Pharmacol. 2023 May 30;14:1192970. doi: 10.3389/fphar.2023.1192970. eCollection 2023.
4
Recent advances in the development of RIPK2 modulators for the treatment of inflammatory diseases.
Front Pharmacol. 2023 Mar 7;14:1127722. doi: 10.3389/fphar.2023.1127722. eCollection 2023.
5
Design, synthesis and biological evaluation of 4-aminoquinoline derivatives as receptor-interacting protein kinase 2 (RIPK2) inhibitors.
J Enzyme Inhib Med Chem. 2023 Dec;38(1):282-293. doi: 10.1080/14756366.2022.2148317.
6
Immune Modulation of Allergic Asthma by Early Pharmacological Inhibition of RIP2.
Immunohorizons. 2020 Dec 18;4(12):825-836. doi: 10.4049/immunohorizons.2000073.
本文引用的文献
1
Synergistic interactions between NOD receptors and TLRs: Mechanisms and clinical implications.
J Leukoc Biol. 2019 Apr;105(4):669-680. doi: 10.1002/JLB.2RU0718-290R. Epub 2018 Dec 5.
2
Identification of Quinoline-Based RIP2 Kinase Inhibitors with an Improved Therapeutic Index to the hERG Ion Channel.
ACS Med Chem Lett. 2018 Sep 26;9(10):1039-1044. doi: 10.1021/acsmedchemlett.8b00344. eCollection 2018 Oct 11.
3
RIP2 filament formation is required for NOD2 dependent NF-κB signalling.
Nat Commun. 2018 Oct 2;9(1):4043. doi: 10.1038/s41467-018-06451-3.
4
Disruption of XIAP-RIP2 Association Blocks NOD2-Mediated Inflammatory Signaling.
Mol Cell. 2018 Feb 15;69(4):551-565.e7. doi: 10.1016/j.molcel.2018.01.016.
5
Identification of Potent and Selective RIPK2 Inhibitors for the Treatment of Inflammatory Diseases.
ACS Med Chem Lett. 2017 Sep 27;8(10):1048-1053. doi: 10.1021/acsmedchemlett.7b00258. eCollection 2017 Oct 12.
6
Twenty years on: the impact of fragments on drug discovery.
Nat Rev Drug Discov. 2016 Sep;15(9):605-619. doi: 10.1038/nrd.2016.109. Epub 2016 Jul 15.
7
The Identification and Pharmacological Characterization of 6-(tert-Butylsulfonyl)-N-(5-fluoro-1H-indazol-3-yl)quinolin-4-amine (GSK583), a Highly Potent and Selective Inhibitor of RIP2 Kinase.
J Med Chem. 2016 May 26;59(10):4867-80. doi: 10.1021/acs.jmedchem.6b00211. Epub 2016 May 4.
8
Crystal structures of human RIP2 kinase catalytic domain complexed with ATP-competitive inhibitors: Foundations for understanding inhibitor selectivity.
Bioorg Med Chem. 2015 Nov 1;23(21):7000-6. doi: 10.1016/j.bmc.2015.09.038. Epub 2015 Sep 25.
9
Inflammatory Signaling by NOD-RIPK2 Is Inhibited by Clinically Relevant Type II Kinase Inhibitors.
Chem Biol. 2015 Sep 17;22(9):1174-84. doi: 10.1016/j.chembiol.2015.07.017. Epub 2015 Aug 27.
10
In vivo inhibition of RIPK2 kinase alleviates inflammatory disease.
J Biol Chem. 2014 Oct 24;289(43):29651-64. doi: 10.1074/jbc.M114.591388. Epub 2014 Sep 11.
Zotero 插件